Appropriate selection of PARP inhibitors in ovarian cancer
M Smith, B Pothuri - Current Treatment Options in Oncology, 2022 - Springer
Opinion statement Poly-ADP-ribose polymerase inhibitors (PARPi) are a class of anti-cancer
drugs that target DNA repair pathways and have shown promising efficacy in patients with …
drugs that target DNA repair pathways and have shown promising efficacy in patients with …
Maintenance treatment of newly diagnosed advanced ovarian cancer: time for a paradigm shift?
Simple Summary Advanced epithelial ovarian cancer has a poor prognosis, but targeted
therapies have been developed and are providing new hope. We reviewed recent results …
therapies have been developed and are providing new hope. We reviewed recent results …
The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 …
Y Zhu, K Liu, H Cao, H Zhu - Journal of ovarian research, 2023 - Springer
Introduction In 2023, the final PAOLA-1 trial (NCT02477644) survival data were published
documenting the benefits of therapy consisting of olaparib plus bevacizumab for patients …
documenting the benefits of therapy consisting of olaparib plus bevacizumab for patients …
Cost-effectiveness analysis of olaparib in combination with bevacizumab compared with bevacizumab monotherapy for the first-line maintenance treatment of …
D Elsea, L Fan, A Mihai, FE Moustaid… - PharmacoEconomics …, 2022 - Springer
Background In the PAOLA-1 trial, olaparib plus bevacizumab demonstrated significant
clinical benefit following partial or complete response to platinum-based chemotherapy in …
clinical benefit following partial or complete response to platinum-based chemotherapy in …
Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations
CM Zettler, DL De Silva, VS Blinder… - JAMA Network …, 2024 - jamanetwork.com
Importance The OlympiA trial found that 1 year of adjuvant olaparib therapy can improve
distant disease-free survival and overall survival from early-stage breast cancer in patients …
distant disease-free survival and overall survival from early-stage breast cancer in patients …
Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
Y Shu, Y Liu, X He, Y Ding, Q Zhang - Frontiers in Pharmacology, 2022 - frontiersin.org
Objective: The aim of this study was to investigate the cost-effectiveness of olaparib as the
maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a …
maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a …
[HTML][HTML] Cost-effectiveness analysis of germline and somatic BRCA testing in patients with advanced ovarian cancer
J Jang, Y Kim, JH Kim, SM Cho… - Annals of laboratory …, 2023 - synapse.koreamed.org
Background BRCA testing is necessary for establishing a management strategy for ovarian
cancer. Several BRCA testing strategies, including germline and somatic testing, are …
cancer. Several BRCA testing strategies, including germline and somatic testing, are …
Cost-effectiveness of PARP inhibitors in malignancies: A systematic review
H Ding, C He, Y Tong, Q Fang, X Mi, L Chen, W Xin… - Plos one, 2022 - journals.plos.org
Objectives Poly (ADP-ribose) polymerase inhibitor (PARPi) have become a mainstay for the
treatment of BRCA-mutant malignancies. PARPis are likely to be more effective but also …
treatment of BRCA-mutant malignancies. PARPis are likely to be more effective but also …
Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia
CM Yong, PAP Yehgambaram, SWH Lee - Plos one, 2024 - journals.plos.org
Introduction Ovarian cancer is one of the most common cancer among women in Malaysia.
Patients with ovarian cancer are often diagnosed at an advanced stage. Despite initial …
Patients with ovarian cancer are often diagnosed at an advanced stage. Despite initial …
Cost-effectiveness analysis of biomarker testing to guide first-line PARP inhibitor maintenance for patients with advanced ovarian cancer after response to first-line …
D Elsea, D Muston, L Fan, A Mihai, Y Meng, A Kasle… - Targeted Oncology, 2023 - Springer
Background Poly (ADP-ribose) polymerase inhibitor maintenance treatments are available
for platinum-sensitive advanced ovarian cancer. Olaparib (O) is available for BRCA mutation …
for platinum-sensitive advanced ovarian cancer. Olaparib (O) is available for BRCA mutation …